Lists are presented of references to all known publications describing cell properties that serve to characterize (i) known strains of HeLa and purported human cell lines indicated as HeLa contaminants, (ii) strains of human cell lines contaminated with human but non-HeLa cells, and (iii) strains of cells contaminated by cells from one or more other species. Frequencies of cell cross-contaminations are cited and references are presented to relatively simple techniques that could serve to detect such contamination.
Four related nontumorigenic and tumorigenic HeLa x fibroblast intraspecific human hybrid cell lines were analyzed to determine whether specific chromosome(s) are associated with the control of tumorigenic expression. The loss of one copy each of both chromosome 11 and chromosome 14 were associated, with a high degree of statistical significance, with the expression of tumorigenicity in two segregants derived from the original nontumorigenic hybrid population. Although the parental origin of the chromosomes could not be established in this study, our preliminary results suggest that complex, genetically determined, regulatory interactions may operate in the control of neoplastic expression.
Chromosome banding revealed marked chromosomes characteristic of HeLa cells in cultures designated HEK, HEK/HRV, HBT-3, HBT-39B, MA160, and a strain of SA-4TxS-Husa(1). Ohter HeLa cell characteristics found were glucose-6-phosphate dehydrogense type A mobility and lack the Y chromosome. Conventional chromosome analysis and immunological and enzymatic technique serve to monitor species specificity and racial origin of the donor. Chromosome banding, however, can monitor intralinear karyotype peculiarity and its evolution during long-term cultivation.
A list is presented of references to all known publications on properties which have served to relate strains of HeLa cells to each other as well as to indict other purported human cell lines as HeLa cell contaminants. Eleven additional cell lines not previously indicted are described. When they exhibit (i) type A (fast) mobility for glucose-6-phosphate dehydrogenase, (ii) phosphoglucomutase type 1 at locus 1 and locus 3, (iii) absence of a Y chromosome by fluorescent staining, and (iv) possession of a complex of trypsin-Giemsa banded marker chromosomes present in known HeLa cells, then cell substrates regardless of designation should be considered de facto strains of HeLa.
We have used chromosome-specific repetitive sequences to detect the most common human aneuploidies prenatally. Together chromosome 21, 13, 18, X, and Y aneuploidy comprises 95% of the chromosome abnormalities that result in a high risk of abnormal phenotypes at birth. The X, Y, and 18 repetitive probes work reliably in multiple tissue types including directly examined and cultured amniocytes, chorionic villus cells, lymphocytes, and cultured fibroblasts. The probe that detects both chromosomes 13 and 21 routinely gives results in each cell type tested except directly studied amniocytes which can be interpreted in seven-ninths of the cases with protocol 1 and all tested samples with protocol 2. Our protocols diagnosed trisomy 21 in a 23-week fetus with low maternal serum AFP and a trisomy 18 in a direct chorionic villus sample 2 working days after the samples were obtained. Trisomy 21 also has been ruled out in a CVS karyotype first thought to be 47,XY, +21. These studies reflect the potential value of in situ hybridization to provide a more rapid, less expensive means to screen most at-risk fetal populations with less effort in first world cytogenetic laboratories, and to provide economical cytogenetic services in less developed countries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.